Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Intratumoral Injection of Carbon Nanoparticle Iron Suspension (CNSI-Fe) in Combination With Radiotherapy in Patients With Solid Tumors

NCT07491783 is registered in ClinicalTrials.gov with Sichuan Enray Pharmaceutical Sciences Company as lead sponsor.

NCT NCT07491783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07491783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Intratumoral Injection of Carbon Nanoparticle Iron Suspension (CNSI-Fe) in Combination With Radiotherapy in Patients With Solid Tumors
Lead sponsor
Sichuan Enray Pharmaceutical Sciences Company
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 27, 2026
Completion date
December 30, 2028
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc, soft tissue cancer